Skip to content
Open access

A cross-model single-cell atlas reveals conserved involvement of osteopontin in polycystic kidney disease

Jul 2026 · JCI Insight · Vol 11 · 0 citations · 38 references
Medicine

TL;DR

An integrated single-cell RNA sequencing atlas across mouse models of PKD is constructed, mapping changes in cell type composition, gene expression, and intercellular signaling networks across the whole atlas and within individual models.

Abstract

Polycystic kidney disease (PKD) arises from mutations in cilia-associated genes, such as PKD1 and PKD2, expressed in renal epithelial cells, leading to progressive kidney dysfunction and end-stage kidney disease. Patients with PKD exhibit significant heterogeneity in disease progression, largely due to genetic and environmental modifiers. Like patients, mouse models of PKD also exhibit significant heterogeneity with regards to the gene mutated, age of disease onset, and rate of disease progression. To elucidate the cellular and molecular consequences of these variables, we constructed an integrated single-cell RNA sequencing (scRNA-seq) atlas across mouse models of PKD, mapping changes in cell type composition, gene expression, and intercellular signaling networks across the whole atlas and within individual models. Across models, scRNA-seq data revealed increased Spp1 (osteopontin) expression and signaling from PKD-enriched clusters. Global deletion of Spp1 in Pkd1RC/RC mice resulted in a modest reduction in cyst severity and improved kidney function. From these studies, we created a freely available, searchable website (https://bmblx.bmi.osumc.edu/scPKD/) that can be used to identify cross- and intra-model changes in gene expression, guiding researchers to new therapeutic targets for treating PKD.

Read PDF

Similar papers

Review Open access Aug 2026

Modeling Complex Developmental Disease: The Case of Polycystic Kidney Disease

Underused Drosophila melanogaster offers high genomic and pathway conservation, a wealth of genetic tools, and rapid generation times, making it a reliable and sustainable model for mechanistic, genome-wide, and precision medicine studies.

Jay Deloriea, Cody Casey, Lexee Shearer et al. · 0 citations
Review Jul 2026

Modulation of Cyst Growth in Autosomal Dominant Polycystic Kidney Disease: Mechanistic Insights and Therapeutic Opportunities.

A model in which cyst growth arises from mutually reinforcing signaling, metabolic, and transcriptional programs is synthesized, which support a model in which cyst growth arises from mutually reinforcing signaling, metabolic, and transcriptional programs.

R. Ursu, B. Buchholz, K. Skoczynski · 0 citations
Aug 2026

ATP6AP2 dysregulation as a central hub in DMD pathogenesis: An integrated multi-omics and therapeutic study.

It is demonstrated that TMZ mitigates dystrophic pathology by targeting the ATP6AP2 signaling axis and dampening macrophage-mediated inflammatory responses, highlighting its potential as a novel immunopharmacological therapeutic strategy for DMD.

Lin Zhou, Yu Zhang, Xinxin Tan et al. · 0 citations
Open access Aug 2026

Genetic and pharmaceutical targeting of Suv39h1 ameliorates renal fibrosis by unlocking CXCL10 transcription.

A critical role for the lysine methyltransferase Suv39h1 in regulating fibroblast-myofibroblast transition (FMyT) and renal fibrosis is identified and Suv39h1-mediated regulation as a previously unrecognized facet of renal fibrogenesis is identified.

Xiao-Yan Wu, Ya-Jun Luo, Caiyi Wu et al. · 0 citations
Open access Jul 2026

Single-cell analysis of the progeria arterial wall reveals progerin-induced progressive, cell type-specific dysfunction and somatic mutation accumulation

It is shown that progerin leads to somatic mutation accumulation particularly in VSMCs, highlighting the need for early, cell-type-specific therapeutic intervention in HGPS to prevent permanent vascular tissue damage.

Lara G. Merino, Gwladys Revêchon, Santhilal Subhash et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.